Chen, Xin
Amar, Norhan https://orcid.org/0000-0002-9921-824X
Zhu, Yuankui
Wang, Chunguang
Xia, Chunjiao
Yang, Xiaoqing
Wu, Dongde
Feng, Mingqian https://orcid.org/0000-0002-0654-8224
Clinical trials referenced in this document:
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Targeted therapy in cervical cancer
https://doi.org/10.1136/esmoopen-2018-000462
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
41 External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS ≥ 1 and CPS ≥ 10
https://doi.org/10.1136/jitc-2022-sitc2022.0041
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.e15137
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
https://doi.org/10.1136/jitc-2020-000785
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
https://doi.org/10.1007/s12325-025-03142-6
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
Funding for this research was provided by:
2. Fundamental Research Funds for the Central Universities (2662016PY113)
2. Fundamental Research Funds for the Central Universities (2662017PY111)
2. Fundamental Research Funds for the Central Universities (2662019YJ013)
1. National Natural Science Foundation of China (31670943)
3. Applied Basic Research Program of Wuhan Science and Technology Bureau (2017060201010195)
4. Bethune Medical Program of Jilin Provincial Science and Technology Department (20160101125JC)